Nanosyrinx has appointed Edwin Moses as its new Chair.
Edwin replaces Stephen Taylor, who has led the board since the company's inception.
Edwin is a C-level executive in the life sciences industry, bringing more than 30 years of experience from over 20 life science companies.
He is currently the chair of Achilles Therapeutics, LabGenius and Avantium.
He has a track record of building and scaling biotech platforms, raising more than EUR €700m in equity and debt financing to date.
Prior to his addition to Nanosyrinx, Edwin was the CEO of Ablynx, until its takeover by Sanofi.
His appointment as Chair will help support Nanosyrinx's executive team in maximising the value of its nanosyringe platform, which can be done through a combination of in-house pipeline development and commercial partnerships.
Nanosyrinx's CEO, Dr Joe Healey, commented: “Edwin has significant experience as a successful CEO and Chair, with extensive involvement in biotech fundraising, strategic commercial partnerships and successful exits. We are thrilled to have him joining as Chair of our Board as we drive forward with our ambitious plans."
"He joins us at a pivotal stage alongside this financing, which places us in a well-capitalised position to further develop our intracellular drug delivery technology to realise its full potential in developing medicines. We would like to thank Steve for all his help over the years, and recognise the instrumental part he has played in getting the company to where it is today.”
